Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
about
Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3ADrug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsA modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients.Torsades de pointes associated with methadone and voriconazole.Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and MetabolismOpioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk managementInhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.Pharmacology and clinical use of voriconazole.Pharmacogenomics of the triazole antifungal agent voriconazole.Update on the optimal use of voriconazole for invasive fungal infections.Is oral methadone better than placebo or other oral/transdermal opioids in the management of pain?Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Methadone: a review of drug-drug and pathophysiological interactions.Serotonin syndrome caused by fentanyl and methadone in a burn injury.Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.
P2860
Q24317436-D4B35AE0-1281-4D9F-B939-8302894BF2DDQ28071256-E17F8217-154E-46EA-B5C2-47BD344D04EBQ34179339-B6D26F7D-90C8-4160-BCAE-C90DA6D6E5A6Q34527805-1C6D4350-E338-49ED-89F6-8FB2E67462BCQ35211432-06EECB93-E3E3-4B46-A707-21BA67850162Q36342286-DBD5E757-BC7B-4D6D-AE32-32F8890E03D2Q36392325-09D4432C-36B4-4651-AD4F-E929B3421FF2Q37358704-5C537DF0-A257-41EF-B3AC-04525A2E13DEQ37631831-91EAAD46-9E03-4396-8EB7-A210FAF5C7E0Q37641375-664C5C87-26C3-4B95-A12B-831AC41B81ACQ37892536-B10C9BFF-9664-4835-8E35-25D1CDA3951FQ37892901-A9BFEBA9-2D49-4774-A45C-16517B594177Q37894995-E7866525-DCB6-4E13-978F-0E6048AD1968Q37904672-118A1E2B-97CB-4FB9-ABCE-AA67A6A0A593Q37950478-1DF8F1FB-5146-4958-B52D-9A307F323050Q47758109-4BB24589-9D47-47B6-AC54-13533B105B4CQ51579656-C163E66E-8898-42F5-961E-358256A00801Q53544619-7DAA8CF6-F915-4676-BB9D-81430E17773B
P2860
Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Pharmacokinetic interaction be ...... patients on methadone therapy.
@en
Pharmacokinetic interaction be ...... patients on methadone therapy.
@nl
type
label
Pharmacokinetic interaction be ...... patients on methadone therapy.
@en
Pharmacokinetic interaction be ...... patients on methadone therapy.
@nl
prefLabel
Pharmacokinetic interaction be ...... patients on methadone therapy.
@en
Pharmacokinetic interaction be ...... patients on methadone therapy.
@nl
P2093
P2860
P356
P1476
Pharmacokinetic interaction be ...... patients on methadone therapy.
@en
P2093
Amarnath Sharma
Eugene Somoza
Grover Foster
Robert Labadie
P2860
P304
P356
10.1128/AAC.00559-06
P407
P577
2006-10-30T00:00:00Z